EWA
CPRX

EP Wealth Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

EP Wealth Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$838K Buy
26,669
+147
+0.6% +$4.34K ﹤0.01% 813
2026
Q1 		$657K Sell
26,522
-450
-2% -$10.7K ﹤0.01% 791
2025
Q4 		$630K Buy
+26,972
New +$601K ﹤0.01% 772
2025
Q2 		$262K Buy
12,063
+28
+0.2% +$661 ﹤0.01% 1100
2025
Q1 		$292K Buy
12,035
+1,504
+14% +$33.9K ﹤0.01% 921
2024
Q4 		$220K Buy
+10,531
New +$226K ﹤0.01% 1026

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EP Wealth Advisors's CPRX Position: Q2 2026 in Review

EP Wealth Advisors increased its Catalyst Pharmaceutical (CPRX) stake by 0.55% in Q2 2026, buying an estimated $4.34K and bringing the position to 26,669 shares worth $838K. The position accounts for ﹤0.01% of the portfolio, ranked #813.

EP Wealth Advisors first reported a position in CPRX in Q4 2024 and has held it in 6 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • EP Wealth Advisors held 26,669 shares of Catalyst Pharmaceutical worth $838K as of Q2 2026.
  • EP Wealth Advisors bought 147 Catalyst Pharmaceutical shares in Q2 2026, an estimated $4.34K.
  • Catalyst Pharmaceutical made up ﹤0.01% of EP Wealth Advisors's portfolio in Q2 2026, its #813 holding.
  • EP Wealth Advisors first reported a position in Catalyst Pharmaceutical in Q4 2024 and has held it in 6 quarters since.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on EP Wealth Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.